Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
On 26 September 2025, Japan's Minister of Finance Katsunobu Kato announced the establishment of the Japan Strategic Investment Facility, a JBIC-administered financing vehicle operationalising the USD 550bn investment pledge from the July 2025 US-Japan tariff and investment agreement. The facility launched 1 October 2025 and runs through March 2029, supporting the overseas expansion of Japanese companies across nine economic-security sectors: semiconductors, pharmaceuticals, steel, shipbuilding, critical minerals, aviation, energy, automobiles, and AI/quantum technology. Funding draws on three sources — dollar-denominated JBIC bonds, yen-denominated Japanese government loans to JBIC, and a "supplemental" transfer from Japan's USD 1.324tn foreign-currency reserves — with private-sector loans and NEXI-backed loan guarantees supplementing JBIC's own financing.
Japan's National Diet passed a partial amendment to the Pharmaceutical and Medical Device Act (PMD Act / 薬機法) on May 14, 2025, promulgated as Law No. 37 of 2025 on May 21. The amendment requires every Marketing Authorization Holder (MAH) to designate a Supply System Manager responsible for reporting supply disruptions to MHLW, and grants MHLW authority to order replacement of key quality personnel when systemic deficiencies are found. It also reforms GMP oversight to a risk-based inspection model and expands the conditional-approval pathway for rare disease and paediatric drugs. Enforcement is staggered across three tranches: November 2025, May 2026, and final full implementation by May 2027.